viral-vector
(4)
Ring Therapeutics
Ring Therapeutics is a Cambridge, Massachusetts biotechnology company founded by Flagship Pioneering to build a new class of gene therapy delivery vectors from anelloviruses - the most abundant and diverse family of viruses that naturally and harmlessly live inside the human body. Because these commensal viruses evade the immune system, Ring's AnelloVector platform aims to solve gene therapy's biggest limitations: the inability to re-dose patients, pre-existing immunity, and narrow tissue targeting. Through its Anellogy discovery platform and AnelloBricks in-vitro manufacturing technology, Ring is engineering re-dosable, tissue-specific, scalable vectors intended to carry a wide range of therapeutic payloads.
Cyagen Biosciences
Cyagen Biosciences is a life-sciences contract research organization that builds custom genetically engineered rodent models - knockout, knockin, conditional, and humanized mice and rats - for academic labs and drug developers. Founded in 2006 and headquartered in Santa Clara, California, with major operations in China, Japan, and Europe, Cyagen has grown into one of the world's largest suppliers of custom mouse and rat models, complemented by stem-cell products and a fast-growing gene-delivery arm, VectorBuilder, that designs and manufactures viral vectors from research through clinical CDMO work.
Dispatch Bio
Dispatch Bio is a Philadelphia-based cancer biotech that emerged from stealth in July 2025 with $216 million to pursue a 'universal' immunotherapy for solid tumors. Its first-in-class Flare platform uses an engineered virus to install a synthetic, tumor-specific antigen on cancer cells while remodeling the tumor's immune-suppressive environment, effectively giving CAR T cells a target where none existed. Founded in 2022 out of the Parker Institute for Cancer Immunotherapy and ARCH Venture Partners, the company is led by CEO Sabah Oney and counts CAR T pioneer Carl June among its scientific co-founders.
Seneca Therapeutics, Inc.
Seneca Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncolytic immunotherapeutics built on SVV-001, a non-pathogenic Seneca Valley Virus that selectively replicates in solid-tumor cells expressing the TEM8/ANTXR1 receptor. Founded by oncolytic-virus pioneer Dr. Paul Hallenbeck, the company pairs SVV-001 with immune modulators and checkpoint inhibitors to spark systemic anti-tumor immunity, and is advancing a Phase I/II trial in high-grade neuroendocrine neoplasms while building a pipeline of armed and neo-antigen viral constructs.